Biotechnology
Medical
Health

Aurinia Pharmaceuticals

$6.47
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.28 (-4.15%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell AUPH and other stocks, options, ETFs, and crypto commission-free!

About

Aurinia Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company, which engages in the development of a therapeutic drug to treat autoimmune diseases particularly lupus nephritis. The company was founded by Robert Foster, Richard Glickman and Michael Martin on June 16, 1993 and is headquartered in Victoria, Canada.

Employees
39
Headquarters
Victoria, British Columbia
Founded
1993
Market Cap
577.13M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
662.96K
High Today
$6.84
Low Today
$6.47
Open Price
$6.67
Volume
522.57K
52 Week High
$7.85
52 Week Low
$5.01

Collections

Biotechnology
Medical
Health
Canada
Pharmaceutical
Therapy
Technology
2013 IPO

News

Seeking AlphaMar 19

Aurinia Pharmaceuticals, Inc. (AUPH) CEO Dr. Richard Glickman on Q4 2018 Results - Earnings Call Transcript

Aurinia Pharmaceuticals, Inc. (NASDAQ:AUPH) Q4 2018 Results Earnings Conference Call March 19, 2019 4:30 PM ET Company Participants Dr. Glenn Schulman - Investor Relations Dr. Richard Glickman - Chief Executive Officer Dennis Bourgeault - Chief Financial Officer Neil Solomons - Chief Medical Officer Conference Call Participants Ed Arce - H. C. Wainwright Joseph Schwartz - Leerink Operator Greetings and welcome to the Aurinia Fourth Quarter and Full Year 2018 Financial Results and Operational Highl...

161
The Motley FoolMar 19

Aurinia Pharmaceuticals Inc (AUPH) Q4 2018 Earnings Conference Call Transcript

Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) Q4 2018 Earnings Conference Call March 19, 2019, 4:30 p.m. ET Contents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: Operator Greetings and welcome to the Aurinia fourth quarter and full year 2018 financial results and operational highlights conference call. At this time, all participants are in a listen-only mode. A brief question and answer session will follow the formal presentation. If anyone should require operator assista...

865
BusinessWireMar 19

Aurinia Reports Fourth Quarter and Full Year 2018 Financial Results and Operational Highlights

VICTORIA, British Columbia--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (“Aurinia” or the “Company”) today reported its financial results for the fourth quarter and year ended December 31, 2018. Amounts, unless specified otherwise, are expressed in U.S. dollars. 2018 and Recent Highlights Notice of Allowance from the United States Patent and Trademark Office (“USPTO”) for claims which have the potential to cover voclosporin’s method of use and dosing protocol for lupus nephriti...

414

Earnings

-$0.21
-$0.15
-$0.09
-$0.03
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Estimated
-$0.14 per share
Actual
-$0.17 per share

Popular Stocks

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.